Author

Ethan R Senior

Observed names: E. Senior, Ethan Senior

Institution: University of Leeds

Observed institutions: University of Leeds, Cancer Research UK, Cancer Research UK Clinical Trials Unit, UCB Pharma (Belgium)

OpenAlex ID: A5113612366

IMWG Frailty Score-Adjusted Therapy Delivery Reduces the Early Mortality Risk in Newly Diagnosed Tne Multiple Myeloma: Results of the UK Myeloma Research Alliance (UK-MRA) Myeloma XIV Fitness Trial

2024 · Gordon Cook, Charlotte Pawlyn, et al. · Blood · 15

Dynamic Frailty Assessment in Transplant Non-Eligible Newly Diagnosed Myeloma Patients: Initial Data from UK Myeloma Research Alliance (UK-MRA) Myeloma XIV (FiTNEss): A Frailty-Adjusted Therapy Study

2023 · Gordon Cook, Charlotte Pawlyn, et al. · Blood · 12

Ixazomib as consolidation and maintenance versus observation in patients with relapsed multiple myeloma eligible for salvage autologous stem-cell transplantation (Myeloma XII [ACCoRD]): interim analysis of a multicentre, open-label, randomised, phase 3 trial

2024 · Gordon Cook, A John Ashcroft, et al. · The Lancet Haematology · 11

INVEST: A phase Ib window of opportunity study of atezolizumab administered either intravesically or direct tumour injection in patients with bladder cancer prior to radical cystectomy.

2024 · Syed A. Hussain, Jamie B. Oughton, et al. · Journal of Clinical Oncology · 2

A phase Ib window of opportunity study of atezolizumab administered intravesically or direct injection in patients undergoing radical cystectomy for bladder cancer: Results of the single dose cohorts.

2025 · Syed A. Hussain, Jamie B. Oughton, et al. · Journal of Clinical Oncology · 1

Health-Related Quality of Life (HRQoL) in Fit, Unfit and Frail Patients Enrolled in Fitness (UK-MRA Myeloma XIV): A Cross Sectional Study

2023 · Orla McCourt, David Allan Cairns, et al. · Blood · 1

INtraVESical immunoTherapy ( INVEST ) prior to radical cystectomy for bladder cancer: trial protocol

2026 · Ruby Lister‐Whelan, Ethan Senior, et al. · British Journal of Urology

Is IMWG frailty-score-adjusted dosing the right approach to improve toxicity and outcomes in FRAIL patients? Results from the UK-MRA FiTNEss trial in newly diagnosed myeloma patients ineligible for ASCT.

2025 · Charlotte Pawlyn, Kara-Louise Royle, et al. · Blood

Cost-Effectiveness of Frailty-Adjusted Therapy in Transplant Non-Eligible Patients with Newly Diagnosed Multiple Myeloma - an Economic Evaluation of the Fitness Trial

2024 · Bryony Dawkins, Georgios Gkountouras, et al. · Blood

Ixazomib-Based Consolidation and Maintenance Prolongs Progression-Free Survival after Salvage Autologous Stem Cell Transplantation (sASCT): Results from Interim Analysis of UK-MRA Myeloma XII (ACCoRD)

2023 · Gordon Cook, A J Ashcroft, et al. · Blood

PND2 Dopamine Agonists and Dyskinesia in Advanced Parkinson's Disease: A Network Meta-Analysis of Rotigotine, Pramipexole and Ropinirole As Adjunct Therapy to Levodopa

2012 · E. Senior, P. Dedeken, et al. · Value in Health

Works count: 11

Citation count: 42

H-index: 3

I10-index: 3